EUVIMEDEUVIMED entdecken
Crossref

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M Elhossiny, Minu K Srivastava, Namrata S Patil, Kiandra A Smith, Rajiv Jesudason und 15 weitere

Cancer Cell · 2024-03 · 42 (3) · 429-443.e4

DOI: 10.1016/j.ccell.2024.01.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-03. Verfasst von Barzin Y Nabet und 26 weiteren Autor:innen. Beteiligte Einrichtung: Genentech Inc., South San Francisco CA, USA. Electronic address: nabet.barzin@gene.com. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 207-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: NCI NIH HHS, F. Hoffmann-La Roche, Genentech Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaHumansImmune Checkpoint InhibitorsCarboplatinEtoposideImmunotherapy

Stichwörter der Autor:innen

IMpower133atezolizumabimmune checkpoint blockadeimmunotherapymolecular subtypingsmall cell lung cancertranscriptomicstumor-associated macrophages

Substanzen

Immune Checkpoint InhibitorsCarboplatinEtoposide

Autor:innen und Institutionen

  • Genentech Inc., South San Francisco CA, USA. Electronic address: nabet.barzin@gene.com.
  • Genentech Inc., South San Francisco CA, USA.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Genentech Inc., South San Francisco CA, USA; Rancho Biosciences, San Diego, CA, USA.
  • Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-8593, USA; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390,…

Förderung

  • NCI NIH HHS
  • F. Hoffmann-La Roche
  • Genentech Inc

Zitieren

APA

Nabet, B. Y., Hamidi, H., Lee, M. C., Banchereau, R., Morris, S., Adler, L., Gayevskiy, V., Elhossiny, A. M., Srivastava, M. K., Patil, N. S., Smith, K. A., Jesudason, R., Chan, C., Chang, P. S., Fernandez, M., Rost, S., McGinnis, L. M., Koeppen, H., Gay, C. M., …, & Shames, D. S. (2024). Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell, 42(3), 429-443.e4. https://doi.org/10.1016/j.ccell.2024.01.010

Vancouver

Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42(3):429-443.e4. doi:10.1016/j.ccell.2024.01.010

BibTeX
@article{Nabet2024,
  author = {Nabet, Barzin Y and Hamidi, Habib and Lee, Myung Chang and Banchereau, Romain and Morris, Stefanie and Adler, Leah and Gayevskiy, Velimir and Elhossiny, Ahmed M and Srivastava, Minu K and Patil, Namrata S and Smith, Kiandra A and Jesudason, Rajiv and Chan, Caleb and Chang, Patrick S and Fernandez, Matthew and Rost, Sandra and McGinnis, Lisa M and Koeppen, Hartmut and Gay, Carl M and Minna, John D and Heymach, John V and Chan, Joseph M and Rudin, Charles M and Byers, Lauren A and Liu, Stephen V and Reck, Martin and Shames, David S},
  title = {Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {3},
  pages = {429--443.e4},
  doi = {10.1016/j.ccell.2024.01.010}
}
Kostenlos starten →